Linaclotide (Linzess)

FDA-approved product existsPeptideImmune & gut

Awaiting review, BioHarmony verdict

Not yet scored. Queued for review; until then rely on the status and sources below.

What is Linaclotide (Linzess)?

FDA-approved linaclotide is marketed as Linzess for irritable bowel syndrome with constipation and chronic idiopathic constipation, with age- and indication-specific dosing in the label.

Saved on this device only.

Dosing as published

Source-reported figures only. This page does not calculate a personal dose.

Approved labelLINZESS prescribing information for IBS-C, chronic idiopathic constipation, and pediatric functional constipation
PopulationAdults and pediatric patients covered by the approved LINZESS indications
DoseAdults: 290 mcg daily for IBS-C, or 145 mcg or 72 mcg daily for chronic idiopathic constipation. Pediatric dosing is 145 mcg daily for IBS-C age 7 and older and 72 mcg daily for functional constipation age 2 and older.
RouteOral capsule on an empty stomach at least 30 minutes before a meal
FrequencyOnce daily
DurationLong-term use within the approved indication
PreparationReady-to-use 72 mcg, 145 mcg, and 290 mcg capsules; no reconstitution. The label provides water, applesauce, and feeding-tube administration instructions for patients unable to swallow the capsule whole.
Source: Dosage and Administration sections 2.1-2.2; Dosage Forms and Strengths section 3

More reported protocols

Members

Members can compare additional reported doses, schedules, and preparation notes.

Trust & sourcing

  1. Last revieweddone
  2. Next reviewupcoming
US approvalFDA-approved product exists
CompoundingFDA-approved product exists; compounded copies are not FDA approved

Primary sources

The Ultimate Peptides Guide

Spot stronger candidates, weak evidence, and seller red flags before you buy.

Free. Includes evidence and regulatory updates. Unsubscribe anytime.